Standigm signs MoU with Merck Korea for AI drug discovery research

South Korea-based Standigm Inc. has announced the signing of a Memorandum of Understanding (MoU) with Merck Korea, for artificial intelligence (AI)-based drug discovery research. The MoU signing took place at the headquarters of Standigm, attended by Sojeong Yun, Chief Executive Officer of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MoU, Standigm will accelerate its drug discovery research by adopting Merck’s AI software SYNTHIA. which can help Standigm’s novel compound synthesis. SYNTHIA is a computer-aided retrosynthetic design tool and unites network theory, modern high-power computing, and expert chemical knowledge to rapidly design synthetic pathways. As a leading workflow AI drug discovery company, Standigm has actively conducted research on AI technology in organic synthesis at its own Synthetic Research Centre, established last year.